Can a pulsatile drug schedule beat brain metastases in lung cancer?

This trial is testing a higher, every-other-day dose of the drug furmonertinib in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study will compare this high-dose schedule to the standard daily dose to see if it controls the disease better and has acceptable side effects. About 42 participants will choose or be assigned to one of the two dosing schedules and be followed until their disease worsens or side effects become too severe.